During the forecast period 2023 to 2033, the Chronic Hepatitis B Virus Testing Market Sales is expected to grow at a value of 6.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Chronic Hepatitis B Virus Testing is expected to rise up to a market valuation of US$ 1790 Million. Growth of the market can be attributed to high prevalence of chronic HBV infection worldwide, increasing public awareness about the importance of early diagnosis and treatment, and the availability of advanced diagnostic technologies.
Another factor driving the growth of the market is the increasing public awareness about the importance of early diagnosis and treatment of chronic HBV infection. As more people become aware of the risks associated with chronic HBV infection and the importance of early intervention, the demand for diagnostic tests is likely to increase. Additionally, government initiatives aimed at increasing public awareness and improving access to testing and treatment are expected to further drive the growth of the Chronic Hepatitis B Virus Testing Market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16778
The availability of advanced diagnostic technologies is also contributing to the growth of the market. Advances in serological assays, nucleic acid tests, and imaging technologies have led to the development of more accurate and reliable diagnostic tests for chronic HBV infection. These tests are also becoming more accessible and affordable, making it easier for patients to access testing and treatment.
Key Takeaways:
- Chronic Hepatitis B Virus Testing market is expected to grow at a value of 6.9% CAGR in the forecast period 2023 to 2033.
- By product type, EIA kits are expected to hold 53% of the market share in 2023 for Chronic Hepatitis B Virus Testing market.
- North America is expected to possess 44% market share for Chronic Hepatitis B Virus Testing market in 2023.
- Europe Chronic Hepatitis B Virus Testing market size is expected to possess 39% market share in 2023.
“High prevalence of the disease has created a significant demand for accurate and reliable diagnostic tests to detect and monitor the infection, driving the growth of the Chronic Hepatitis B Virus Testing Market” States an FMI analyst
Competitive Landscape:
Key players in the Chronic Hepatitis B Virus Testing market are Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., Abbott Laboratories, Meridian Bioscience
- Gilead Sciences’ has partnered with the Hepatitis B Foundation and the Task Force for Global Health to launch the Hepatitis B Rural Outreach and Testing (HB R.O.O.T.) program. This program aims to increase HBV testing and diagnosis in rural areas of the United States, where HBV testing and diagnosis rates are often low.
- One of Janssen’s key contributions in the area of HBV testing is their development of a blood test that can detect the presence of HBV DNA in the bloodstream. The test, called the COBAS AmpliPrep/COBAS TaqMan HBV Test, is used to monitor the amount of virus in patients with chronic HBV infection and to evaluate the effectiveness of antiviral treatment.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Chronic Hepatitis B Virus Testing market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Product Type (Enzyme Immunoassay Kits and Point-of-Care Testing Kits), End User (Hospitals, Clinics, Diagnostic Centers, Home Care), Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-16778
Key Segments:
Product Type:
- Enzyme Immunoassay Kits
- Hepatitis B Surface Antigen Test
- Anti-Hepatitis B Surface Antibody Test
- Anti-Hepatitis B Core Antibody Test
- Point-of-Care Testing Kits
End User:
- Hospitals
- Clinics
- Diagnostic Centers
- Home Care
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube